ReviewPharmacoEconomics2016
Big Data and Health Economics: Strengths, Weaknesses, Opportunities and Threats.
Review in PharmacoEconomics, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed.
- COVID-19 and access to subsidized dental care according to household income. A register-based population study from Norway.Acta odontologica Scandinavica · 2025Article
- Assessment of expanded programme on immunization routine data quality in the upper east region of Ghana.BMC health services research · 2024Article
- The Use of Big Data in Personalized Healthcare to Reduce Inventory Waste and Optimize Patient Treatment.Journal of personalized medicine · 2024Review
- Analysis of the Recomposition of Norms and Representations in the Field of Psychiatry and Mental Health in the Age of Electronic Mental Health: Qualitative Study.JMIR mental health · 2019Article
- A Review of the Challenges of Using Biomedical Big Data for Economic Evaluations of Precision Medicine.Applied health economics and health policy · 2019Review
- Data integration of electronic medical record under administrative decentralization of medical insurance and healthcare in China: a case study.Israel journal of health policy research · 2019Article
- Reliability of Paper-Based Routine Documentation in Psychiatric Inpatient Care and Recommendations for Further Improvement.Frontiers in psychiatry · 2019Article
- Towards precision medicine; a new biomedical cosmology.Medicine, health care, and philosophy · 2018Article
- Moving low value care lists into action: prioritizing candidate health technologies for reassessment using administrative data.BMC health services research · 2018Article
- Administration of oral fluoroquinolone and the risk of rhegmatogenous retinal detachment: A nationwide population-based study in Korea.PloS one · 2018Article
- Big Data analysis to improve care for people living with serious illness: The potential to use new emerging technology in palliative care.Palliative medicine · 2018Article
- Article
- Impact of initial medication non-adherence on use of healthcare services and sick leave: a longitudinal study in a large primary care cohort in Spain.The British journal of general practice : the journal of the Royal College of General Practitioners · 2017Article
- Emerging Use of Early Health Technology Assessment in Medical Product Development: A Scoping Review of the Literature.PharmacoEconomics · 2017Article
- A methodological protocol for selecting and quantifying low-value prescribing practices in routinely collected data: an Australian case study.Implementation science : IS · 2017Article
- From Population Databases to Research and Informed Health Decisions and Policy.Frontiers in public health · 2017Article
- Big Data Science: Opportunities and Challenges to Address Minority Health and Health Disparities in the 21st Century.Ethnicity & disease · 2017Review
- Precision Health Economics and Outcomes Research to Support Precision Medicine: Big Data Meets Patient Heterogeneity on the Road to Value.Journal of personalized medicine · 2016Article
- Realising the Value of Linked Data to Health Economic Analyses of Cancer Care: A Case Study of Cancer 2015.PharmacoEconomics · 2016Article
- Big Data and Its Role in Health Economics and Outcomes Research: A Collection of Perspectives on Data Sources, Measurement, and Analysis.PharmacoEconomics · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
'Big data' is the collective name for the increasing capacity of information systems to collect and store large volumes of data, which are often unstructured and time stamped, and to analyse these data by using regression and other statistical techniques. This is a review of the potential applications of big data and health economics, using a SWOT (strengths, weaknesses, opportunities, threats) approach. In health economics, large pseudonymized databases, such as the planned care.data programme in the UK, have the potential to increase understanding of how drugs work in the real world, taking into account adherence, co-morbidities, interactions and side effects. This 'real-world evidence' has applications in individualized medicine. More routine and larger-scale cost and outcomes data collection will make health economic analyses more disease specific and population specific but may require new skill sets. There is potential for biomonitoring and lifestyle data to inform health economic analyses and public health policy.
Indexed as
Identifiers
26093888What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.